96
Participants
Start Date
July 7, 2020
Primary Completion Date
March 1, 2024
Study Completion Date
May 1, 2024
GQ1001
anti-HER2 antibody drug conjugate
RECRUITING
Scientia Clinical Research Limited, Randwick
COMPLETED
Cabrini Institute in Melbourne, Australia, Melbourne
COMPLETED
M.D. Anderson Cancer Center, Houston
RECRUITING
Beijing Tongren Hospital Affiliated to Capital University of Medical Sciences, Beijing
RECRUITING
Chinese PLA general hospital, Beijing
RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
RECRUITING
Shanghai Ninth People's Hospital affiliated with the Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
Zhongshan Hospital, Shanghai
RECRUITING
Ruijin Hospital, Affiliated to Shanghai Jiaotong University, Shanghai
RECRUITING
Shanghai East Hospital, Shanghai
RECRUITING
Changhai Hospital of Shanghai, Shanghai
RECRUITING
Shanghai Pulmonary Hospital, Shanghai
RECRUITING
The first affiliated hospital of Bengbu medical college, Bengbu
RECRUITING
Shandong Tumor Hospital, Jinan
RECRUITING
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Hubei Huazhong University of Science and provincial Cancer Hospital Affiliated Union Hospital of Tongji Medical College, Wuhan
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Southern Medical University Hospital in the south, Guangzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Guangzhou
RECRUITING
West China School of Medicine and West China Hospital, Sichuan University, Chengdu
GeneQuantum Healthcare (Suzhou) Co., Ltd.
INDUSTRY